# Cardio Intelligence

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cardio-intelligence

- Industry: Healthcare IT
- Headquarters: Tokyo, Japan
- Website: www.cardio-i.com
- Total disclosed funding: $5M
- Latest round: Series B (Nov 20, 2025)
- Investors on record: 10

## About

Based in Tokyo, Japan, and founded in 2019, Cardio Intelligence Inc. engages in research, develops, and sells automatic diagnosis systems that utilize artificial intelligence technology. The company delivers arrhythmia diagnostics worldwide through AI, Cardio Intelligence leverages vast ECG data and expert annotations to build high-precision AI solutions. In March 2026, Cardio Intelligence raised an undisclosed amount in series B funding from Altomos Investment Co., Ltd.

The company’s flagship product, the SmartRobin AI Series, is a long-term ECG analysis software that automatically detects atrial fibrillation with high accuracy. This series also includes explainable AI to aid non-cardiology specialists in making definitive diagnoses and pre-disease diagnostic AI that detects atrial fibrillation signs during non-attack periods, a technology for which it has filed a patent.

The company plans to use its proceeds from November 2025 funding for product development, enhancing its internal framework and international expansion.

## Funding rounds

- Series B, Nov 20, 2025 — Tokai Tokyo Investment, Iwahira Business Creation Capital, Shin Nippon Biomedical Laboratories, LTD., Fujita Innovation Capital
- Series A, Nov 22, 2022, $1.4M — Nissay Capital
- Series A, Aug 15, 2022, $3.2M — Daiwa Corporate Investment, SMBC Venture Capital, Shizuoka Capital, ANRI, Gemseki Inc.
- Seed, Aug 27, 2020, $0.3M — ANRI

## Investors

- ANRI (https://capitalatlas.ai/funds/anri) — Seed, Series A
- Daiwa Corporate Investment (https://capitalatlas.ai/funds/daiwa-corporate-investment) — Series A
- SMBC Venture Capital (https://capitalatlas.ai/funds/smbc-venture-capital) — Series A
- Shizuoka Capital (https://capitalatlas.ai/funds/shizuoka-capital) — Series A
- Gemseki Inc. — Series A
- Nissay Capital (https://capitalatlas.ai/funds/nissay-capital) — Series A
- Tokai Tokyo Investment (https://capitalatlas.ai/funds/tokai-tokyo-investment) — Series B
- Iwahira Business Creation Capital — Series B
- Shin Nippon Biomedical Laboratories, LTD. — Series B
- Fujita Innovation Capital (https://capitalatlas.ai/funds/fujita-innovation-capital) — Series B